Patent details

EP1470107 Title: FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

Basic Information

Publication number:
EP1470107
PCT Application Number:
PCT/CA/2003/000084
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP037007408
PCT Publication Number:
WO/2003/062200
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
French Title of Invention:
CYCLOALKANOINDOLES A SUBSTITUTION FLUOR, COMPOSITIONS CONTENANT DE TELS COMPOSES, ET PROCEDES DE TRAITEMENT
German Title of Invention:
FLUORO SUBSTITUIERTE CYCLOALKANINDOLE UND DEREN VERWENDUNG ALS PROSTAGLANDIN D2 REZEPTOR ANTAGONISTEN
SPC Number:
91534

Dates

Filing date:
22/01/2003
Grant date:
19/11/2008
EP Publication Date:
19/11/2008
PCT Publication Date:
31/07/2003
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
27/10/2004
EP B1 Publication Date:
19/11/2008
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
22/01/2015
Expiration date:
22/01/2023
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
22/01/2003
 
 

Name:
Merck Frosst Canada Ltd.
Address:
16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1, Canada (CA)

Agent

Name:
MARKS & CLERK LLP
From:
25/11/2008
Address:
BP 1775, 1017, LUXEMBOURG, Luxembourg (LU)
To:

Inventor

1

Name:
BERTHELETTE Carl
Address:
Canada (CA)

2

Name:
WANG Zhaoyin
Address:
Canada (CA)

3

Name:
STURINO Claudio
Address:
Canada (CA)

4

Name:
LACHANCE Nicolas
Address:
Canada (CA)

5

Name:
LI Lianhai
Address:
Canada (CA)

Priority

Priority Number:
351384 P
Priority Date:
24/01/2002
Priority Country:
United States (US)

Classification

Main IPC Class:
C07D 209/80;
Filing date Document type Number of pages
12/08/2022 Request For Change 1
02/09/2022 Outgoing Correspondence 56